Zepbound (tirzepatide) is a glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist that is FDA-approved along with increased physical activity and a reduced-calorie diet for chronic weight management in adults with a starting body mass index (BMI) of: 30 kg/m^2 or higher (obesity) or 27 kg/m^2 or higher (overweight) with at least one weight-related condition such as high cholesterol, high blood pressure (hypertension), type 2 diabetes, heart disease, or obstructive sleep apnea
Based on the chart below (Source: Hims House), GLP-1 Revenue which includes compounded, generic, and branded forms was $145M in Q4
Since the custom prescriptions generated by KLOwen Software reduce the number of doctor-intensive appointments, Dr
As medication costs continue to rise and new therapeutic options emerge, effective approaches for benefit management such as this will become increasingly valuable to all healthcare stakeholders
Initially approved for managing Type 2 diabetes, semaglutide has also been shown to promote weight loss in certain doses, making it a popular choice for individuals seeking metabolic health benefits
